Physician profile
Ejo John
NPI 1639550841
$1,625.03
in general payments reported to CMS, 2019-2025
15 companies · $606 in 2025
The $606 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2023: $316 · 2024: $578 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,500.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $264.59 | 2023-2025 | Tavneos, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $211.81 | 2023-2024 | Farxiga |
| Travere Therapeutics, INC. | $174.29 | 2023-2025 | Filspari |
| Ardelyx, INC. | $140.53 | 2024-2025 | Ibsrela |
| Medtronic, INC. | $126.95 | 2025 | Symplicity G3 |
| Janssen Pharmaceuticals, INC | $124.98 | 2019 | |
| Calliditas Therapeutics US INC. | $106.62 | 2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $86.99 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $82.28 | 2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.41 | 2024-2025 | Jardiance |
| Akebia Therapeutics INC | $59.86 | 2025 | Vafseo |
| Aurinia Pharma U.S., INC. | $50.85 | 2023-2024 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $50.74 | 2023-2025 | Jynarque |
| Vifor Pharma, INC. | $42.98 | 2024-2025 | Veltassa |
| Kyowa Kirin, INC. | $27.15 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ejo John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.